Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025

Data presented at SSIEM 2024 Annual Symposium Twice-daily oral treatment with JNT-517 at 150mg dose delivered highly statistically significant mean blood phenylalanine reduction of 60% versus baseline in individuals with PKU JNT-517 was safe and well tolerated with no serious adverse events observed JNT-517 has been granted Orphan Drug Designation by the U.S. FDA… The post Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025 appeared first on Jnana Therapeutics .